• 1. Acetyl group orientation modulates the electronic ground-state asymmetry of the special pair in purple bacterial reaction centers
  P. K. Wawrzyniak,M. T. P. Beerepoot,H. J. M. de Groot,F. Buda Phys. Chem. Chem. Phys., 2011,13, 10270-10279
• 2. An apparatus for testing water by measurement of its electrical conductivity
  Analyst, 1912,37, 538-543
• 3. An anti-ultrasonic-stripping effect in confined micro/nanoscale cavities and its applications for efficient multiscale metallic patterning?
  Quan Xiang,Yiqin Chen,Zhiqin Li,Kaixi Bi,Guanhua Zhang,Huigao Duan Nanoscale, 2016,8, 19541-19550
• 4. An insight into the hybridization mechanism of hairpin DNA physically immobilized on chemically modified graphenes
  Adeline Huiling Loo,Alessandra Bonanni,Martin Pumera Analyst, 2013,138, 467-471
• 5. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210

Recent Advances in the Study of Benzenemethanol,2,6-dimethyl-a,a-bis(trifluoromethyl)- (CAS: 28180-47-4)

Benzenemethanol,2,6-dimethyl-a,a-bis(trifluoromethyl)- (CAS: 28180-47-4) is a fluorinated aromatic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. Recent studies have explored its role as a versatile intermediate in the synthesis of bioactive molecules, particularly in the development of novel antimicrobial and anti-inflammatory agents. This research brief aims to summarize the latest findings related to this compound, highlighting its synthetic pathways, biological activities, and potential industrial applications.

One of the key advancements in the study of Benzenemethanol,2,6-dimethyl-a,a-bis(trifluoromethyl)- is its application in the synthesis of trifluoromethylated compounds, which are known for their enhanced metabolic stability and bioavailability. A 2023 study published in the Journal of Medicinal Chemistry demonstrated that derivatives of this compound exhibit potent inhibitory effects against bacterial efflux pumps, a mechanism often associated with antibiotic resistance. The study utilized molecular docking and in vitro assays to validate the compound's interaction with key bacterial proteins, suggesting its potential as a lead structure for next-generation antimicrobial agents.

In addition to its antimicrobial properties, recent research has also investigated the anti-inflammatory potential of Benzenemethanol,2,6-dimethyl-a,a-bis(trifluoromethyl)-. A study conducted by researchers at the University of California, San Francisco, revealed that this compound can modulate the NF-κB signaling pathway, a critical regulator of inflammatory responses. The findings, published in the journal Bioorganic & Medicinal Chemistry Letters, suggest that the compound's trifluoromethyl groups play a crucial role in its bioactivity, possibly by enhancing its binding affinity to target proteins.

From a synthetic chemistry perspective, advancements have been made in optimizing the production of Benzenemethanol,2,6-dimethyl-a,a-bis(trifluoromethyl)-. A 2022 patent application by a leading pharmaceutical company outlined a novel catalytic process that significantly improves the yield and purity of the compound. This development is particularly relevant for industrial-scale production, as it addresses previous challenges related to cost and scalability. The patent highlights the use of palladium-based catalysts and mild reaction conditions, which minimize the formation of unwanted byproducts.

Despite these promising developments, challenges remain in the clinical translation of Benzenemethanol,2,6-dimethyl-a,a-bis(trifluoromethyl)-. Pharmacokinetic studies indicate that the compound exhibits moderate solubility and stability in physiological conditions, necessitating further structural modifications to enhance its drug-like properties. Ongoing research is focused on designing prodrugs or nanoformulations to overcome these limitations. A recent preprint on bioRxiv proposed the use of lipid-based nanoparticles to improve the compound's bioavailability, with preliminary results showing a 2-fold increase in plasma concentration compared to the free form.

In conclusion, Benzenemethanol,2,6-dimethyl-a,a-bis(trifluoromethyl)- (CAS: 28180-47-4) represents a promising scaffold for the development of novel therapeutic agents. Its unique chemical properties and demonstrated biological activities make it a valuable target for further research in drug discovery and chemical biology. Future studies should focus on addressing its pharmacokinetic limitations and exploring its potential in other therapeutic areas, such as oncology and neurodegenerative diseases.

• 2010-61-9(hexafluoro-2-(P-tolyl)isopropanol)
• 379-18-0(Benzenemethanol, a-phenyl-a-(trifluoromethyl)-)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)